Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780869 · ClinicalTrials.gov registry record · NA
HEMOBLAST Pivotal Clinical Investigation
A NA study, sponsored by Biom'Up France SAS.
- Completed
- Registry status
- NA
- Development phase
- 258
- Enrollment target
NCT02780869 is a NA study that has completed, run by Biom'Up France SAS. The registered enrollment target is 258 participants.
The verdict
NCT02780869, a NA study, has completed, sponsored by Biom'Up France SAS.
- COMPLETED
- Registry status
- NA
- Development phase
- 258 participants
- Enrollment target
Study Summary
The purpose of this prospective, randomized, controlled study is to evaluate the safety and efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device, absorbable gelatin sponge USP with thrombin.
Interventions
- DEVICE HEMOBLAST Bellows
- DEVICE Absorbable gelatin sponge, USP with thrombin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2016-07-18 |
| Est. Completion | 2017-03-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780869
The ClinicalTrials.gov registry entry for NCT02780869 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biom'Up France SAS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HEMOBLAST Bellows is the first listed.
NCT02780869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780869 about?
NCT02780869 is a clinical study titled "HEMOBLAST Pivotal Clinical Investigation". The purpose of this prospective, randomized, controlled study is to evaluate the safety and efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device, absorbable gelatin sponge USP with thrombin.
What is the current status of trial NCT02780869?
This trial is currently completed. It is a NA study. The enrollment target is 258 participants. The study started on 2016-07-18. Estimated completion is 2017-03-27.
What interventions are being tested in trial NCT02780869?
The interventions under investigation include: HEMOBLAST Bellows (DEVICE), Absorbable gelatin sponge, USP with thrombin (DEVICE).
Who is sponsoring clinical trial NCT02780869?
This trial is sponsored by Biom'Up France SAS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.